Prof Daniel Petrylak speaks to ecancer about the primary analysis of TROPHY-U-01 cohort 2 study which was presented at ASCO GU 2023. TROPHY-U-01 cohort 2 is a phase 2 study of sacituzumab govitecan in platinum-ineligible patients with metastatic urothelial cancer that progressed after prior checkpoint inhibitor therapy. 

The findings of the study found sacituzumab govitecan monotherapy demonstrated a high response rate with an overall manageable safety profile in PT-ineligible patients with mUC who progressed after CPI therapy.

Prof Petrylak concludes by discussing how this could affect the future treatment of urothelial cancer.